BIO.B vs GKOS
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
BIO.B · Bio-Rad Laboratories-B$379.50 ▲ 0.00%
GKOS · Glaukos$224.41 ▲ 2.01%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- BIO.B +24.3%
- GKOS +154.0%
Head to head
| Metric | BIO.B | GKOS |
|---|---|---|
| Price | $379.50 | $224.41 |
| Change today | ▲ 0.00% | ▲ 2.01% |
| Market cap | $10.21B | $13.28B |
| Return, 3 months | +12.6% | +23.7% |
| Return, year to date | +22.1% | +98.8% |
| Return, 1 year | +24.3% | +167.6% |
| P/E (TTM) | 10.1 | – |
| P/B | 1.3 | 18.5 |
| P/E percentile vs own 5y | 96th | 2nd |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | -0.1% | +58.0% |
| Net profit growth (YoY) | +16.9% | +112.4% |
| Gross margin | 51.9% | 64.8% |
| Operating margin | 8.7% | -25.3% |
| Net margin | 8.6% | -24.6% |
| Return on equity | 3.1% | -22.8% |
| Analyst target vs. price | – | +5.8% |
| Analyst buy share | – | 100% |
| RSI (14) | 97 | 64 |
| 30-day volatility | 12.0% | 98.5% |
| Max drawdown, 1 year | -20.4% | -28.4% |
| Trend read | Strong uptrend | Strong uptrend |
| Analyst consensus | – | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- GKOS is the largest of the group by market value.
- GKOS has returned the most over the past year.
- GKOS is growing revenue fastest.
- BIO.B keeps the most profit per dollar of sales.
- BIO.B has been the calmest stock over the last 30 days.